All Phenotypes Apc<tm2.1Cip> MGI Mouse

About Help FAQ

Phenotypes associated with this allele

Allele Symbol
Allele Name
Allele ID

Apc^tm2.1Cip
targeted mutation 2, Christine Perret
MGI:3521822

Summary

11 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Apc^tm2.1Cip/Apc^tm2.1Cip	involves: 129P2/OlaHsd * C57BL/6N	MGI:3522324
cn2	Apc^tm2.1Cip/Apc^tm2.1Cip Tg(Ttr-cre/Esr1*)1Vco/0	B6.Cg-Apc^tm2.1Cip Tg(Ttr-cre/Esr1*)1Vco	MGI:5430588
cn3	Apc^tm2.1Cip/Apc^tm2.1Cip Lect2^tm1Ymg/Lect2^tm1Ymg Tg(Ttr-cre/Esr1*)1Vco/0	B6.Cg-Lect2^tm1Ymg Apc^tm2.1Cip Tg(Ttr-cre/Esr1*)1Vco	MGI:5430589
cn4	Apc^tm2.1Cip/Apc⁺ Lrig1^{tm1.1(cre/ERT2)Rjc}/Lrig1⁺	involves: 129 * 129P2/OlaHsd * C57BL/6	MGI:5432136
cn5	Apc^tm2.1Cip/Apc⁺ Kras^tm4Tyj/Kras⁺ Tg(Fabp1-cre)1Jig/0	involves: 129P2/OlaHsd * 129S4/SvJae * FVB	MGI:3776028
cn6	Apc^tm2.1Cip/Apc⁺ Lgr5^{tm1(cre/ERT2)Cle}/Lgr5⁺	involves: 129P2/OlaHsd * C57BL/6	MGI:5432137
cn7	Apc^tm2.1Cip/Apc⁺ Atg7^tm1Tchi/Atg7^tm1Tchi Tg(Vil1-cre/ERT2)23Syr/0	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2	MGI:5702420
cn8	Apc^tm2.1Cip/Apc⁺ Tg(Vil1-cre)20Syr/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:4461183
cn9	Apc^tm2.1Cip/Apc⁺ Tg(Vil1-cre/ERT2)23Syr/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:5702414
cn10	Apc^tm2.1Cip/Apc^tm2.1Cip Tg(Vil1-cre/ERT2)23Syr/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2	MGI:5702422
cn11	Apc^tm2.1Cip/Apc⁺ Tg(Fabp1-cre)1Jig/0	involves: 129P2/OlaHsd * FVB/N	MGI:3776025

Allelic Composition	Apc^tm2.1Cip/Apc^tm2.1Cip
Genetic Background	involves: 129P2/OlaHsd * C57BL/6N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:94721 )

• injection with 10⁹ pfu adenovirus cre resulted in 50% mortality within 2 weeks and 95% mortality within 2 months

• lower doses of adenovirus cre resulted in decreased mortality (15% mortality at 2 months with 0.5 x 10⁹ pfu) or no mortality (0.25 x 10⁹ pfu)

neoplasm

increased hepatocellular carcinoma incidence ( J:94721 )

• 9 months after injection with 0.5 x 10⁹ pfu adenovirus cre of the 4 out of 6 livers that still contained hepatocytes with the recombined allele developed micronodular preneoplastic foci and/or hepatocellular carcinomas

liver/biliary system

liver hyperplasia ( J:94721 )

• 7 days after injection with 10⁹ pfu of adenovirus cre the livers of homozygous mutants were 60% larger than heterozygous controls

• hepatocytes containing the recombined allele are selectively lost over time, 9 months after injection with 0.5 x 10⁹ pfu adenovirus cre 6 out of 10 livers still contained hepatocytes with the recombined allele

increased hepatocellular carcinoma incidence ( J:94721 )

growth/size/body

liver hyperplasia ( J:94721 )

• 7 days after injection with 10⁹ pfu of adenovirus cre the livers of homozygous mutants were 60% larger than heterozygous controls

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
hepatocellular carcinoma		DOID:684	OMIM:114550	J:94721

Allelic Composition	Apc^tm2.1Cip/Apc^tm2.1Cip Tg(Ttr-cre/Esr1*)1Vco/0
Genetic Background	B6.Cg-Apc^tm2.1Cip Tg(Ttr-cre/Esr1*)1Vco

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Tg(Ttr-cre/Esr1*)1Vco mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

hematopoietic system

decreased NK T cell number ( J:184496 )

• tamoxifen-treated mutants exhibit a decrease (14.9% vs. 28.6% in controls) of invariant NKT (iNKT) cells in the entire population of immune cells; the diminished proportion of iNKTs is more pronounced in the CD4+ iNKT cells than in the CD4- iNKT cells

abnormal NK T cell physiology ( J:184496 )

• iNKT activation level is higher in the liver of tamoxifen-treated mutants than in controls

immune system

decreased NK T cell number ( J:184496 )

abnormal NK T cell physiology ( J:184496 )

• iNKT activation level is higher in the liver of tamoxifen-treated mutants than in controls

increased interferon-gamma secretion ( J:184496 )

• CD4+ and CD4- subpopulations of iNKTs isolated from mutant livers produce higher amounts of IFN-gamma compared to controls

increased interleukin-4 secretion ( J:184496 )

• CD4+ and CD4- subpopulations of iNKTs isolated from mutant livers produce higher amounts of IL-4 compared to controls

liver inflammation ( J:184496 )

• tamoxifen-treated mutants exhibit higher absolute numbers of most types of immune cells in the liver, including Kupffer cells, granulocytes, NK, B lymphocytes, and conventional T cells

• mutant livers are more sensitive to ConA-induced hepatitis than controls

liver/biliary system

liver inflammation ( J:184496 )

• tamoxifen-treated mutants exhibit higher absolute numbers of most types of immune cells in the liver, including Kupffer cells, granulocytes, NK, B lymphocytes, and conventional T cells

• mutant livers are more sensitive to ConA-induced hepatitis than controls

abnormal liver morphology ( J:184496 )

• mutants injected with tamoxifen exhibit significantly higher total numbers of nonparenchymal cells (NPCs) in the liver

enlarged liver ( J:184496 )

• mutants injected with tamoxifen develop progressive hepatomegaly

growth/size/body

enlarged liver ( J:184496 )

• mutants injected with tamoxifen develop progressive hepatomegaly

Allelic Composition	Apc^tm2.1Cip/Apc^tm2.1Cip Lect2^tm1Ymg/Lect2^tm1Ymg Tg(Ttr-cre/Esr1*)1Vco/0
Genetic Background	B6.Cg-Lect2^tm1Ymg Apc^tm2.1Cip Tg(Ttr-cre/Esr1*)1Vco

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Lect2^tm1Ymg mutation (0 available); any Lect2 mutation (14 available)
Tg(Ttr-cre/Esr1*)1Vco mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:184496 )

• tamoxifen treated mutants exhibit a decrease in survival rate

liver/biliary system

increased hepatocyte apoptosis ( J:184496 )

• increase in liver apoptosis in tamoxifen treated mutants

liver inflammation ( J:184496 )

• liver inflammation is increased in tamoxifen treated mutants compared to single Apc mutants

abnormal liver morphology ( J:184496 )

• livers of tamoxifen treated mutants exhibit a flaccid and loose texture compared to livers from single Apc homozygotes

• mutants injected with tamoxifen exhibit significantly higher total numbers of nonparenchymal cells (NPCs) in the liver

hepatic necrosis ( J:184496 )

• in tamoxifen treated mutants

immune system

increased NK T cell number ( J:184496 )

• number of iNKT cells in the liver is increased in tamoxifen-treated double mutants compared to single Apc mutants

abnormal neutrophil physiology ( J:184496 )

• liver infiltrating immune cells of tamoxifen treated mutants have an increase in neutrophils compared to infiltrating immune cells in single Apc mutants

abnormal NK T cell physiology ( J:184496 )

• invariant NKTs (iNKTs) are more activated in tamoxifen treated double mutant livers than in single Apc mutant livers

abnormal chemokine level ( J:184496 )

• chemokines in the liver of tamoxifen treated mutants, such as Cxcl1, Cxcl12, and Cxcl12 are induced to higher levels in double mutants than in single Apc mutants

decreased interferon-gamma secretion ( J:184496 )

• CD4- iNKTs from tamoxifen treated mutants produce less IFN-gamma than CD4- iNKTs of single Apc mutants

increased interleukin-4 secretion ( J:184496 )

• CD4- iNKTs from tamoxifen treated mutants produce more IL-4 than CD4- iNKTs of single Apc mutants

liver inflammation ( J:184496 )

• liver inflammation is increased in tamoxifen treated mutants compared to single Apc mutants

homeostasis/metabolism

abnormal circulating enzyme level ( J:184496 )

• serum transaminase levels are higher in tamoxifen treated mutants than in single Apc homozygotes

abnormal chemokine level ( J:184496 )

• chemokines in the liver of tamoxifen treated mutants, such as Cxcl1, Cxcl12, and Cxcl12 are induced to higher levels in double mutants than in single Apc mutants

hematopoietic system

increased NK T cell number ( J:184496 )

• number of iNKT cells in the liver is increased in tamoxifen-treated double mutants compared to single Apc mutants

abnormal neutrophil physiology ( J:184496 )

• liver infiltrating immune cells of tamoxifen treated mutants have an increase in neutrophils compared to infiltrating immune cells in single Apc mutants

abnormal NK T cell physiology ( J:184496 )

• invariant NKTs (iNKTs) are more activated in tamoxifen treated double mutant livers than in single Apc mutant livers

cellular

increased hepatocyte apoptosis ( J:184496 )

• increase in liver apoptosis in tamoxifen treated mutants

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Lrig1^{tm1.1(cre/ERT2)Rjc}/Lrig1⁺
Genetic Background	involves: 129 * 129P2/OlaHsd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Lrig1^{tm1.1(cre/ERT2)Rjc} mutation (1 available); any Lrig1 mutation (50 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased intestinal adenoma incidence ( J:186084 )

• with tamoxifen treatement, colon tumors are observed by day 50 following Apc^fldeletion with cre induction (and stochastic loss of second Apc allele)

• by day 50 there are multiple distal colonic tumors with no proximal colon tumor burden; tumor phenotype is 100% penetrant

• largest tumors are found in distal colon, many having high grade dysplasia; highest tumor number is observed in jejunum

digestive/alimentary system

increased intestinal adenoma incidence ( J:186084 )

• with tamoxifen treatement, colon tumors are observed by day 50 following Apc^fldeletion with cre induction (and stochastic loss of second Apc allele)

• by day 50 there are multiple distal colonic tumors with no proximal colon tumor burden; tumor phenotype is 100% penetrant

• largest tumors are found in distal colon, many having high grade dysplasia; highest tumor number is observed in jejunum

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Kras^tm4Tyj/Kras⁺ Tg(Fabp1-cre)1Jig/0
Genetic Background	involves: 129P2/OlaHsd * 129S4/SvJae * FVB

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Kras^tm4Tyj mutation (9 available); any Kras mutation (84 available)
Tg(Fabp1-cre)1Jig mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:132357 )

• animals have greatly reduced life-span compared to mutants expressing wild-type Kras

neoplasm

increased intestinal adenocarcinoma incidence ( J:132357 )

• adenocarcinomas show uniform high-grade dysplasia, including large, fused glands with serrated borders, pseudostratified epithelium, loss of apical-basal polarity, and high nucleus to cytoplasm ratio

• mice have more tumors than mutants expressing wild-type Kras

• terminally differentiated cells are absent from tumors

digestive/alimentary system

increased intestinal adenocarcinoma incidence ( J:132357 )

• mice have more tumors than mutants expressing wild-type Kras

• terminally differentiated cells are absent from tumors

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Lgr5^{tm1(cre/ERT2)Cle}/Lgr5⁺
Genetic Background	involves: 129P2/OlaHsd * C57BL/6

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Lgr5^{tm1(cre/ERT2)Cle} mutation (1 available); any Lgr5 mutation (58 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

neoplasm ( J:186084 )

N	• following tamoxifen treatment, no intestinal tumors are observed

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Atg7^tm1Tchi/Atg7^tm1Tchi Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * C57BL/6NCrlj * CBA/JNCrlj * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Atg7^tm1Tchi mutation (3 available); any Atg7 mutation (51 available)
Tg(Vil1-cre/ERT2)23Syr mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

decreased intestinal adenoma incidence ( J:227287 )

• tamoxifen treated mice show fewer and smaller colonic tumors that develop more slowly and have a lower proliferation rate than in single conditional Apc heterozygous mice

• however, prolonged antibiotic treatment of tamoxifen treated mice induces numerous intestinal tumor foci and tamoxifen treated mice administered anti-CD8 antibodies to induce partial depletion of Treg show increased tumor development

digestive/alimentary system

abnormal intestinal goblet cell morphology ( J:227287 )

• abnormal accumulation of granules of mucus in goblet cells in the tumor-free mucosa of tamoxifen treated mice

abnormal Paneth cell morphology ( J:227287 )

• unusually small in tumor-free mucosa of tamoxifen treated mice

decreased intestinal adenoma incidence ( J:227287 )

• tamoxifen treated mice show fewer and smaller colonic tumors that develop more slowly and have a lower proliferation rate than in single conditional Apc heterozygous mice

abnormal gut flora balance ( J:227287 )

• tamoxifen treated mice show altered distribution of gut bacteria, with bacteria occasionally seen within the crypt compartment of the small intestine

• tamoxifen treated mice show a difference in the overall composition of both fecal and ileal microbiota compared to single conditional Apc heterozygotes, with mice showing a high level of Gram+ bacteria related to Firmicutes and low levels of Proteobacteria in feces

• ileal mucosa of tamoxifen treated mice has a higher bacterial diversity than single conditional Apc heterozygotes

abnormal intestine physiology ( J:227287 )

• intestinal permeability is high in tamoxifen treated mice

endocrine/exocrine glands

abnormal Paneth cell morphology ( J:227287 )

• unusually small in tumor-free mucosa of tamoxifen treated mice

hematopoietic system

increased CD103-positive CD11b-low dendritic cell number ( J:227287 )

• proportion of CD103+CD11b- dendritic cell subset involved in T-cell priming is higher in tamoxifen treated mice than in single conditional Apc heterozygous mice

increased CD8-positive, alpha-beta T cell number ( J:227287 )

• the number of Treg and CD8 IFN-gamma T cells in the lamina propria is higher than in single conditional Apc heterozygous mice

• administration of IL-1beta receptor antagonist, anakinra, to tamoxifen treated mice is sufficient to prevent the expansion of cytotoxic CD8+ T cells

increased regulatory T cell number ( J:227287 )

• the number of Treg and CD8 IFN-gamma T cells in the lamina propria is higher than in single conditional Apc heterozygous mice

immune system

increased CD103-positive CD11b-low dendritic cell number ( J:227287 )

• proportion of CD103+CD11b- dendritic cell subset involved in T-cell priming is higher in tamoxifen treated mice than in single conditional Apc heterozygous mice

increased CD8-positive, alpha-beta T cell number ( J:227287 )

• the number of Treg and CD8 IFN-gamma T cells in the lamina propria is higher than in single conditional Apc heterozygous mice

• administration of IL-1beta receptor antagonist, anakinra, to tamoxifen treated mice is sufficient to prevent the expansion of cytotoxic CD8+ T cells

increased regulatory T cell number ( J:227287 )

• the number of Treg and CD8 IFN-gamma T cells in the lamina propria is higher than in single conditional Apc heterozygous mice

abnormal immune system physiology ( J:227287 )

• tamoxifen treated mice show marked infiltration of lymphocytes within the normal mucosa, higher numbers of CD45 and T cells in the small intestine and colon mucosa, influx of CD11c+ cells in the intestinal mucosa compared to single conditional Apc heterozygous mice, indicating promotion of anti-tumor immune responses

increased interleukin-1 beta secretion ( J:227287 )

• immune cells isolated from the lamina propria of tamoxifen treated mice produce high amounts of IL-1beta

increased interleukin-10 secretion ( J:227287 )

• immune cells isolated from the lamina propria of tamoxifen treated mice produce high amounts of IL-10

cellular

abnormal intestinal goblet cell morphology ( J:227287 )

• abnormal accumulation of granules of mucus in goblet cells in the tumor-free mucosa of tamoxifen treated mice

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Tg(Vil1-cre)20Syr/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Tg(Vil1-cre)20Syr mutation (4 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased intestinal adenoma incidence ( J:160399 )

increased colon adenoma incidence ( J:160399 )

digestive/alimentary system

increased intestinal adenoma incidence ( J:160399 )

increased colon adenoma incidence ( J:160399 )

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Tg(Vil1-cre/ERT2)23Syr mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased intestinal adenoma incidence ( J:227287 )

• tamoxifen treated mice develop intestinal adenomas after the sporadic loss of the remaining Apc allele

increased colon adenoma incidence ( J:227287 )

• tamoxifen treated mice develop colon adenomas after the sporadic loss of the remaining Apc allele

homeostasis/metabolism

abnormal autophagy ( J:227287 )

• tamoxifen-treated mice show activation of autophagy in tumoral cells

mortality/aging

decreased tumor-free survival time ( J:227287 )

• tamoxifen treated mice show signs of illness and have to be euthanized at 135 days due to large tumor burden

growth/size/body

cachexia ( J:227287 )

• tamoxifen treated mice show loss of body weight, pale feet and hunching

digestive/alimentary system

rectal prolapse ( J:227287 )

• tumors of tamoxifen treated mice in the distal colon and rectum are associated with frequent rectal prolapse

increased intestinal adenoma incidence ( J:227287 )

• tamoxifen treated mice develop intestinal adenomas after the sporadic loss of the remaining Apc allele

increased colon adenoma incidence ( J:227287 )

• tamoxifen treated mice develop colon adenomas after the sporadic loss of the remaining Apc allele

intestine polyps ( J:227287 )

• in tamoxifen treated mice

• prolonged antibiotic administration of tamoxifen treated mice does not affect severity of polyposis

• metaformin treatment impairs the growth of polyps in tamoxifen-treated mice but does not affect adenoma cell proliferation

abnormal gut flora balance ( J:227287 )

• tamoxifen treated mice show a difference in the overall composition of both fecal and ileal microbiota compared to double conditional mice heterozygous for Apc and homozygous for Atg7, with mice showing high levels of Gram- bacteria mostly from Helicobacter in the feces

• ileal mucosa of tamoxifen treated mice has a lower bacterial diversity than in double conditional mice heterozygous for Apc and homozygous for Atg7

• the ratio of Gram- to Gram+ bacteria is lower in tamoxifen treated mice than in double conditional mice heterozygous for Apc and homozygous for Atg7

cellular

abnormal autophagy ( J:227287 )

• tamoxifen-treated mice show activation of autophagy in tumoral cells

Mouse Models of Human Disease		DO ID	OMIM ID(s)	Ref(s)
colorectal cancer		DOID:9256	OMIM:114500	J:227287

Allelic Composition	Apc^tm2.1Cip/Apc^tm2.1Cip Tg(Vil1-cre/ERT2)23Syr/0
Genetic Background	involves: 129P2/OlaHsd * C57BL/6 * DBA/2

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Tg(Vil1-cre/ERT2)23Syr mutation (1 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

mortality/aging

premature death ( J:98469 )

• mice appear unwell and are moribund 4 days after tamoxifen injection

digestive/alimentary system

abnormal intestinal goblet cell morphology ( J:98469 )

• goblet cells are less numerous in the intestinal epithelium of tamoxifen treated mice

increased small intestinal crypt cell apoptosis ( J:98469 )

• tamoxifen treated mice show numerous apoptotic bodies in the crypts and higher number of apoptotic cells in the elongated crypts

abnormal intestine development ( J:98469 )

• marker analysis indicates that the intestinal mucosa of tamoxifen treated mice lacks differentiation into enterocytes, goblet, or enteroendocrine cells and is committed to the Paneth cell lineage, although most of the cells do not show typical granules indicating that they do not undergo full differentiation to the Paneth cell lineage

abnormal intestinal epithelium morphology ( J:98469 )

• tamoxifen treated mice exhibit an increase in cell proliferation in intestinal epithelium

• tamoxifen treated mice show slowed migration of epithelial cells along the crypt-villus axis in the epithelium

abnormal small intestine crypts of Lieberkuhn morphology ( J:98469 )

• tamoxifen treated mice show dysplasia in the crypt all along the small intestine, including pseudostratification, enlargement of the nuclei, prominent nucleoli, and basophil accumulation

• the crypt compartment of tamoxifen treated mice is greatly expanded

abnormal colon morphology ( J:98469 )

• tamoxifen treated mice show some rare lesions in the proximal colon which show characteristics similar to the small intestinal dysplasia

endocrine/exocrine glands

abnormal small intestine crypts of Lieberkuhn morphology ( J:98469 )

• tamoxifen treated mice show dysplasia in the crypt all along the small intestine, including pseudostratification, enlargement of the nuclei, prominent nucleoli, and basophil accumulation

• the crypt compartment of tamoxifen treated mice is greatly expanded

cellular

abnormal intestinal goblet cell morphology ( J:98469 )

• goblet cells are less numerous in the intestinal epithelium of tamoxifen treated mice

increased small intestinal crypt cell apoptosis ( J:98469 )

• tamoxifen treated mice show numerous apoptotic bodies in the crypts and higher number of apoptotic cells in the elongated crypts

Allelic Composition	Apc^tm2.1Cip/Apc⁺ Tg(Fabp1-cre)1Jig/0
Genetic Background	involves: 129P2/OlaHsd * FVB/N

Find Mice

Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Apc^tm2.1Cip mutation (2 available); any Apc mutation (158 available)
Tg(Fabp1-cre)1Jig mutation (2 available)

♀	phenotype observed in females
♂	phenotype observed in males
N	normal phenotype

neoplasm

increased intestinal adenocarcinoma incidence ( J:132357 )

• focal, pedunculated adencarcinomas develop in the colon; lesions are typically heterogeneous showing both low grade and malignant epithelium

digestive/alimentary system

increased intestinal adenocarcinoma incidence ( J:132357 )

• focal, pedunculated adencarcinomas develop in the colon; lesions are typically heterogeneous showing both low grade and malignant epithelium

Contributing Projects: Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support.	last database update 12/10/2024 MGI 6.24